Navigation Links
A New Milestone in Stem Cell Research

In the first trial of its kind in the world, 60 patients who have recently suffered a major heart attack will be injected with selected stem cells from their own bone marrow during routine coronary bypass surgery.

The Bristol trial will test whether the stem cells will repair heart muscle cells damaged by the heart attack, by preventing late scar formation and hence impaired heart contraction.

Professor Jeremy Pearson, Associate Medical Director of the BHF, said: We hope that this exciting Bristol project will provide information taking us a step nearer to the day when stem cells can be used routinely to help repair damaged hearts.

In a heart attack, part of the heart muscle loses its blood supply (usually due to furring up of the arteries with fatty material) and cells in that part of the heart die, leaving a scar. This reduces the ability of the heart to pump blood around the body.

While the blood supply to the heart can be improved with coronary bypass surgery or angioplasty, thereby reducing the risk of further heart attacks, these techniques do not restore the viability and function of the area already damaged. In 3-6 months after surgery, 20 per cent of patients develop a thinning of the walls of the heart, which in its most extreme form, can lead to congestive heart failure.

Dr Raimondo Ascione, Consultant Cardiac Surgeon, said: I am very grateful to the British Heart Foundation for funding this important trial; the first of its kind worldwide. We have elected to use a very promising stem cell type selected from the patients own bone marrow. This approach ensures no risk of rejection or infection. It also gets around the ethical issues that would result from use of stem cells from embryonic or foetal tissue.

Current treatments aim to keep the patient alive with a heart that is working less efficiently than before the heart attack. Cardiac stem cell therapy aims to repair the damaged h eart as it has the potential to replace the damaged tissue.

In this trial (known as TransACT), all patients will have bone marrow harvested before their heart operation. Then either stem cells from their own bone marrow or a placebo will be injected into the patients damaged hearts during routine coronary bypass surgery. The feasibility and safety of this technique has already been demonstrated.

As a result of the chosen double blind placebo-controlled design, neither the patients nor the surgeon knows whether the patient is going to be injected with stem cells or placebo. This ensures that results are not biased in any way, and is the most powerful way to prove whether or not the new treatment is effective.


'"/>




Related medicine news :

1. Cancer Research: Yet Another Milestone
2. Year 2010 Envisioned to be Milestone Year for Malaria Vaccine
3. Eurand and GSK Reach Development Milestone
4. Kidney Stones - Interesting New Research implicates bacteria as its cause
5. Researchers urge caution in using ear tube surgery
6. Paracetamol May Cause Live Damage Warns Consumer Education and Research Centre
7. Researchers Scale to assess the Severity of Epilepsy in Kids
8. Research of Ritalin
9. Researchers trick Alzheimers Enzyme
10. Researchers find new HIV hiding place
11. A Compilation of recent Diabetes Research articles
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/19/2017)... ... ... Driving Dynamics Inc., announced today it has been selected as a 2017 ... its mission to continually monitor the training marketplace for the best providers of training ... and Safety Training Companies list was based on the following criteria: , ...
(Date:9/19/2017)... ... September 19, 2017 , ... The ISO 9001 standard sets out ... organizations become more efficient and improve customer satisfaction. ISO 9001:2015 was released in 2015 ... with a deadline of September 2018. , As described in this ...
(Date:9/19/2017)... ... ... Bone Solutions Inc. (BSI), an orthobiologics technology company located ... OsteoCrete® bone void filler is designed to assist with bone repair and generation, ... for bone health and development. , “We’re excited to bring this important orthopedic ...
(Date:9/19/2017)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... of its Pflugerville- FM 685 facility. , “We are pleased to announce Dr. ... said Dr. Stephen Van Roekel, Reginal Medical Officer of First Choice Emergency Room – ...
(Date:9/19/2017)... ... September 19, 2017 , ... The Davidson Institute for Talent ... on September 27 at a reception in Washington D.C. The recipients received $50,000, ... Music. , “I am honored to be a Davidson Fellow Laureate,” said Rishab ...
Breaking Medicine News(10 mins):
(Date:9/5/2017)... WAYNE, N.J. , Sept. 5, 2017 /PRNewswire/ ... technology, has created a vibrant charitable donation program ... funds and support congenital heart defect research by ... healthcare providers and the general public are encouraged ... and submit the completed artwork to the ...
(Date:9/1/2017)...  Bayer will present the latest research from across its ... (ESMO) 2017 Congress, September 8-12 in Madrid, Spain ... clinical data on Bayer,s marketed portfolio and late-stage compounds as ... "We value the opportunity to ... at ESMO," said Carsten Brunn , Head of Pharmaceuticals, ...
(Date:8/28/2017)... , Aug. 28, 2017   Aesculight ®, a division of ... surgical lasers. Built on over 20 years of American veterinary laser ... New and Exclusive VetScalpel®Features and Enhancements ... Duclos, DVM, is excising a tumor with his new VetScalpel laser. Dr. ... Lynnwood, WA. ...
Breaking Medicine Technology: